Aspire Biopharma
ASBP | NASDAQ
$8.06
-$0.35 (-4.16%)
At close: Nov 16, 2026, 4:00 PM ET
$8.30
+$0.24 (+2.98%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Aspire Biopharma Company Profile
Company profile explainedCompany Profile
Aspire Biopharma Holdings, Inc. is an emerging pharmaceutical enterprise dedicated to pioneering and commercializing innovative sublingual drug delivery systems within the United States. Its flagship product, Instaprin, is an advanced sublingual aspirin formulation known for being soluble, pH neutral, and rapidly absorbed, making it effective for both cardiovascular emergencies and general pain management. The company is diligently developing a diverse pipeline of orally dissolving formulations. This includes a melatonin-based sleep aid, essential vitamins (D, E, and K), testosterone, and semaglutide. Furthermore, Aspire Biopharma is extending its sublingual development efforts to various therapeutic areas, such as anti-nausea treatments, antipsychotic medications, erectile dysfunction drugs, and seizure control therapies, among others. They are also exploring caffeine products, including a formulation for a single-dose sublingual pre-workout supplement. Established in 2021, the firm's main operational base is situated in Estero, Florida.
Key Executives
| Name | Position |
|---|---|
| Kraig T. Higginson | Interim Chief Executive Officer, President & Executive Chairman of the Board |
| Ernest J. Scheidemann Jr. | Chief Financial Officer |
| Stephen E. Quesenberry | General Counsel & Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 20, 2026 | 8-K/A | [Amend] Current Report |
| Sep 29, 2026 | 8-K | Current Report |
| Sep 09, 2026 | 8-K | Current Report |
| Sep 08, 2026 | 8-K | Current Report |
| Aug 19, 2026 | 8-K | Current Report |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 13, 2026 | 10-Q | Quarterly Report |
| Aug 10, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Aug 10, 2026 | 8-K | Current Report |
| Aug 06, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Aspire Biopharma
| Country | United States |
| IPO Date | Feb 20, 2025 |
| Industry | Medical - Pharmaceuticals |
| Sector | Healthcare |
| Employees | 2 |
| CEO | Kraig T. Higginson |
Contact Details
23150 Fashion Drive Estero,
Florida 33928 United States
Stock Details
| Ticker Symbol | ASBP |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001847345 |
| CUSIP Number | 738920305 |
| ISIN Number | US7389203057 |
| SIC Code | 6770 |
Add to Watchlist
Select watchlists to add or remove ASBP